A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
Rebecca C. Shay, Andrew Nicklawsky, Dexiang Gao, Elaine T. Lam
Topics & Concepts
MedicineAxitinibNivolumabIpilimumabPembrolizumabRenal cell carcinomaAvelumabInternal medicineOncologyKidney cancerUrologyImmunotherapyCancerSunitinibRenal cell carcinoma treatmentHealth Systems, Economic Evaluations, Quality of LifeCancer Immunotherapy and Biomarkers